A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
Status:
Terminated
Trial end date:
2021-09-09
Target enrollment:
Participant gender:
Summary
This is a study to determine the recommended dose of birabresib (MK-8628) for further studies
in participants with acute myeloid leukemia (AML) including AML de novo and AML secondary to
myelodysplastic syndrome (MDS) and in participants with diffuse large B cell lymphoma
(DLBCL). The recommended dose will be established by evaluating dose limiting toxicity (DLT),
safety, tolerability, and early efficacy signals.